CAMBRIDGE, Mass.--(BUSINESS WIRE)--WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients impacted by rare diseases, today announced that it has appointed Michael A. Panzara, M.D., MPH, as head of the company’s neurology franchise. In this new role, Dr. Panzara will oversee WAVE’s portfolio of neurological therapeutic candidates, from target discovery through clinical development, regulatory approval, and post-approval activities.
